Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05301881 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study

Study acronym: COSMO
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 53% 118 → 56 participants
See other at-risk trials from The Netherlands Cancer Institute

Record History

  1. Enrollment reduced: 118 → 56 participants Eligibility criteria expanded, about 26 words · Site details revised at 5 of 7 sitesv6 Show 2 more changesShow less
    • Eligibility criteria expanded, about 26 words
    • Site details revised at 5 of 7 sites

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 5 to 7 Eligibility criteria shortened, about 13 wordsv5 Show 1 more changeShow less
    • Eligibility criteria shortened, about 13 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 1 to 5 Eligibility criteria expanded, about 36 wordsv4 Show 1 more changeShow less
    • Eligibility criteria expanded, about 36 words

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Active, Not Recruiting to Recruiting Start date: Sep 1, 2022 to Apr 17, 2023 · Site details revisedv3 Show 2 more changesShow less
    • Start date: Sep 1, 2022 to Apr 17, 2023
    • Site details revised
  5. Start date changed from estimate of Apr 15, 2022 to Sep 1, 2022 Trial status: Not Yet Recruiting to Active, Not Recruiting · Site contact updatedv2 Show 2 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Site contact updated
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with oligoprogression of metastatic breast cancer during palliative treatment that is amenable to local therapy will be included. The local ablative therapy (LAT) may consist of stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy, surgery or percutaneous ablation.
Trial Details
NCT Number NCT05301881
Lead Sponsor The Netherlands Cancer Institute
Collaborators: Maarten van de Weijden Foundation
Conditions Breast Cancer Invasive, Metastatic Cancer, Oligoprogressive
Enrollment 56 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov